^
    over1year
    Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated (IASLC-WCLC 2023)
    In patients with advanced NSCLC harboring uncommon EGFR mutations, high-dose aumolertinib demonstrated a tolerable safety profile and encouraging antitumor activity in NSCLC pts harboring uncommon EGFR mutations. High-dose aumolertinib is also currently being evaluated in a phase 3 clinical trial for patients with uncommon EGFR mutations (NCT04951648).
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747P • EGFR H773L • EGFR V774M
    |
    Ameile (aumolertinib)
    over1year
    Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations (IASLC-WCLC 2023)
    The second-generation EGFR-TKI afatinib has been shown to be effective against complex rare EGFR mutations like H773L/V774M or G719X/S768I, meanwhile more adverse effects such as diarrhea and rash occur...Telephone follow-up revealed that the patient continued to take aumolertinib in combination with anlotinib until her death in July 2022... A previous report indicated that patients harboring two uncommon mutations were associated with poorer prognosis (mPFS: 6.5 months). However, the AIM study, recently published in ESMO ASIA 2022, demonstrated that aumolertinib had an impressive objective response rate (ORR) of 53.8% and disease control rate (DCR) of 100% in patients with the main rare mutations (G719X/L861Q/S768I). In summary, this case report suggests that EGFR V774M/S768I can be an activating mutation complex and the administration of aumolertinib monotherapy or a combination with anti-angiogenic drug can achieve outstanding clinical benefits for these patients.
    Clinical • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR exon 20 mutation + EGFR V774M + EGFR S768I • EGFR H773L • EGFR V774M
    |
    Gilotrif (afatinib) • Focus V (anlotinib) • Ameile (aumolertinib)
    almost4years
    Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC. (PubMed, J Thorac Oncol)
    No abstract available
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR H773L
    |
    Tagrisso (osimertinib)